Potential of nanopore sequencing for tuberculosis diagnosis and drug resistance detection.

Publication date: Dec 28, 2024

This study evaluates the effectiveness of nanopore sequencing for accurate detection of Mycobacterium tuberculosis pathogens and drug resistance mutations in clinical specimens. A retrospective analysis of 2,421 specimens from suspected tuberculosis patients admitted to Xi’an Chest Hospital from 2022 to 2023 was conducted, with 131 specimens undergoing via real-time, fluorescence-based quantitative Polymerase Chain Reaction (qPCR), simultaneous amplification and testing RNA (RNA), Mycobacterium culture, Mycobacterium smear, and nanopore sequencing. Employing clinical tuberculosis diagnoses as the gold standard, sensitivity, specificity, positive predictive value, negative predictive value, concordance rate, and Kappa coefficient were measured for the five detection techniques. We compared nanopore sequencing with the Melting Curve method to detect drug-resistant gene mutations. Nanopore sequencing has a significantly higher sensitivity (0. 786) for tuberculosis diagnosis compared to qPCR (0. 411), RNA (0. 411), Mycobacterium culture (0. 402), and Mycobacterium smear (0. 241), against the gold-standard clinical diagnosis. It also exhibited a greater concordance rate (0. 809) and Kappa coefficient (0. 488), and outperformed the other methods in terms of the area under the ROC curve. Nanopore sequencing surpassed the Melting Curve method in identifying drug-resistant mutations. Nanopore sequencing significantly enhances the detection of tuberculosis pathogens and drug-resistant genes.

Open Access PDF

Concepts Keywords
Mycobacterium Adult
Nanopore Comparative study
Rna Drug Resistance, Bacterial
Surpassed Drug-resistance genes
Tuberculosis Female
Humans
Male
Mutation
Mycobacterium
Mycobacterium tuberculosis
Nanopore Sequencing
Nanopore sequencing
Retrospective Studies
Sensitivity and Specificity
TB
Tuberculosis
Tuberculosis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Gold
drug DRUGBANK Saquinavir
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease IDO country
drug DRUGBANK Coenzyme M
drug DRUGBANK Huperzine B
disease IDO pathogen
disease IDO assay
drug DRUGBANK Tretamine
disease IDO reagent
drug DRUGBANK Rifampicin
drug DRUGBANK Ademetionine
drug DRUGBANK Phosphate ion
disease IDO bacteria
disease IDO nucleic acid
drug DRUGBANK Water
disease IDO process
drug DRUGBANK Isoniazid
drug DRUGBANK Ethambutol
drug DRUGBANK Pyrazinamide
drug DRUGBANK Medical air
drug DRUGBANK Streptomycin
disease MESH Pulmonary tuberculosis
disease MESH Extrapulmonary tuberculosis
disease MESH Pus
disease IDO blood
drug DRUGBANK Nitazoxanide
disease IDO ribonucleic acid
disease MESH Mutation Frequency
disease MESH infections
pathway REACTOME Methylation
disease IDO quality
drug DRUGBANK Esomeprazole

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *